• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
29
Jul
2015

Data From Texas: VCs, Still Mostly Underwater, Ride Stocks As Long As Possible

/
Luke Timmerman
/
0
/
All, Venture Capital
29 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Jul
2015

Bad Behaviors Creeping Into Biotech During the Boom

/
Luke Timmerman
/
2
/
All, People, The Edge
27 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Jul
2015

The Amgen Seattle Alumni: Where Are They Now?

/
Luke Timmerman
/
1
/
All, People
24 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Jul
2015

The Non-Compete Chill Has Passed: Bristol-Myers, MedImmune Settle Over I-O Star

/
Luke Timmerman
/
0
/
All, Cancer, People
21 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Jul
2015

How Are Biotech VCs Performing in the Boom? You’d Be Surprised (Part 2)

/
Luke Timmerman
/
1
/
All, Venture Capital
21 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Jul
2015

How Are Biotech VCs Performing in the Boom? You’d Be Surprised

/
Luke Timmerman
/
14
/
All, The Edge, Venture Capital
20 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Jul
2015

Forget Price Controls – Value-Based Pricing is the New Threat to Drug Development

/
Troy Wilson
/
7
/
All, Cancer, Drugs
17 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
Jul
2015

Happy (Belated) Independence Day! Timmerman Report is Here to Stay

/
Luke Timmerman
/
4
/
All
09 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Jul
2015

Pay Cut? That’s OK: Wall Street Veterans Find New Purpose in Biotech

/
Luke Timmerman
/
1
/
All, People, The Edge
07 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Jul
2015

Q&A With Shire CEO Flemming Ornskov on Becoming More ‘Biotech-Like’

/
Luke Timmerman
/
0
/
All, People
02 Jul 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Jun
2015

LinkedIn Is Integral to Biotech, But Some Still Don’t Get It

/
Luke Timmerman
/
3
/
All, People, The Edge
29 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Jun
2015

The Cubist Alumni: Where Are They Now?

/
Luke Timmerman
/
2
/
All, People
25 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Jun
2015

The Long Slog For Better Drug Safety Monitoring Is Paying Off

/
Luke Timmerman
/
0
/
All, FDA, The Edge
22 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jun
2015

Like the TR? Tell a Friend to Subscribe, and Enter to Win a T-Shirt

/
Luke Timmerman
/
0
/
All
19 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jun
2015

Who’s Exploring DNA ‘Dark Matter’ for Drug Discovery?

/
Luke Timmerman
/
0
/
All, Genomics
19 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Jun
2015

It’s Time to Re-Think Some Assumptions About Cancer R&D

/
Luke Timmerman
/
4
/
All, Cancer, Drugs, The Edge
15 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Jun
2015

NEA, Polaris Bet $22M on Startup, Xtuit, to Break Down Tumor Microenvironment

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
11 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Jun
2015

Bristol-Myers Should Drop the Bully Act. Non-Competes Are Bad for Biotech

/
Luke Timmerman
/
2
/
All, People, The Edge
08 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Jun
2015

Cancer is Hot, Diabetes is Not: Watch for Drug Safety and Cost Debates at ADA

/
Luke Timmerman
/
5
/
All, Drugs
05 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Jun
2015

Big Pharma Talent Is Flocking to Biotech Startups. Nobody’s Saying ‘Are You Nuts?’

/
Luke Timmerman
/
2
/
All, People, The Edge
01 Jun 2015

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 74 75 76 77 78 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder